Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Samplix logo — Reveal cell function with single-cell resolution.

Samplix

Reveal cell function with single-cell resolution.

Founded 2013 Denmark Denmark 35 employees Venture round Total: $12.67M Biotechnology, Information Technology

General Information

Company Name Samplix
Founded Year 2013
Location Denmark Denmark
Employees 35
Industries Biotechnology, Information Technology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Samplix. To contact Samplix, visit samplix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Samplix compare?

A PDF of Samplix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Samplix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Samplix

Samplix is a Denmark-based biotechnology startup founded in 2013 with a focus on single-cell analysis in immunotherapy research. The company's flagship product, Xdrop, utilizes double emulsion technology to encapsulate living cells and reactive molecules in stable droplets, enabling rapid cell-cell and cell-molecule interactions during incubation. This technology allows for seamless analysis and sorting on flow cytometers, resulting in highly accurate, single-cell resolution results. The latest round of funding, a €7.50M Venture Round investment, was secured on 30 March 2023 from European Innovation Council and Fjord Capital. Samplix's innovative Xdrop and Xdrop Sort solutions cater to the needs of engineered cell therapy research, protein engineering, synthetic biology workflows, and other cell interaction- or cell secretion-based processes. The company's ability to offer a user-friendly workflow without the requirement of prior experience with fluorescence-based cell sorters positions it as a promising player in the biotechnology and information technology industries.

Business keywords: single-cell analysis, immunotherapy research, double emulsion technology, flow cytometry, cell sorting, Xdrop technology, living cells encapsulation, reactive molecules, microenvironment, flow cytometry and sorting, engineered cell therapy research, protein engineering, synthetic biology workflows, cell interaction, cell secretion

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €2.50M 1
European Innovation Council
European Innovation Council
30 Mar 2023
Venture Round €7.50M 2
European Innovation Council
European Innovation Council, Fjord Capital
30 Mar 2023
Grant €2.67M 1
EASME - EU Executive Agency for SMEs
01 Jan 2019

Samplix Alternatives & Competitors

View All Alternatives
Samplix vs
BD Biosciences /Česká republika/
BD Biosciences /Česká republika/ Czech Republic

Vítáme Vás v barevném a inovativním světě průtokové cytometrie.

8 employees
Biotechnology, Health Care
Compare Samplix vs BD Biosciences /Česká republika/
Samplix vs
Sutro Biopharma, Inc.
Sutro Biopharma, Inc. United States

Changing the future of Oncology

IPO
208 employees
Biotechnology, Information Technology
Compare Samplix vs Sutro Biopharma, Inc.
Samplix vs
Autonomous Medical Devices Incorporated
Autonomous Medical Devices Incorporated United States

A medical diagnostics company dedicated to developing and manufacturing point-of-care diagnostic dev...

Grant
54 employees
Biotechnology, Health Care
View all alternatives

FAQ About Samplix

Reveal cell function with single-cell resolution.
Samplix was founded in 2013.
Samplix is headquartered in Denmark.
Samplix operates in Biotechnology and Information Technology. Its work centres on single-cell analysis, immunotherapy research, double emulsion technology and flow cytometry.
Samplix has approximately 35 employees.
Samplix has completed 3 funding rounds, raising a total of $12.67M. The latest funding stage is Venture round.
Top alternatives and competitors to Samplix include BD Biosciences /Česká republika/, Sutro Biopharma, Inc., Autonomous Medical Devices Incorporated, Digi.Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Samplix and BD Biosciences /Česká republika/ are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Samplix, https://bouncewatch.com/company/samplix, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout